Group 1 - The company Jinghua Pharmaceutical (002349.SZ) announced that its subsidiary Shandong Luhua Senxuan New Materials Co., Ltd. led the formulation of the industry standard for 1,3-Dioxolane, which has been approved by the National Standardization Administration and will be implemented on March 1, 2026 [1]

Group 1 - The company, Jinghua Pharmaceutical, announced that its subsidiary, Shandong Luhuasenxuan New Materials Co., Ltd., led the formulation of the industry standard for "1,3-Dioxolane" [1] - The industry standard has been approved by the National Standardization Administration and will be officially implemented on March 1, 2026 [1]

Group 1 - The core point of the article is that the industry standard for "1,3-Dioxolane" has been approved by the National Standardization Administration and will be implemented starting March 1, 2026 [1] Group 2 - The standard was led by Shandong Luhuasenxuan New Materials Co., Ltd., a subsidiary of Jinghua Pharmaceutical [1] - The announcement was made by the Ministry of Industry and Information Technology [1]

精华制药公告，近日，由公司孙公司山东鲁化森萱新材料有限公司牵头制定的《13-二氧戊环》行业标 准（标准号：HG/T6387-2025）通过国家标委会评审，并经中华人民共和国工业和信息化部发布公告， 该标准于2026年3月1日起正式实施。 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-036 精华制药集团股份有限公司 关于孙公司牵头制定产品行业标准的公告 公司将以此行业标准发布、实施为新的起点，不断提高产品质量和管控措施， 进一步树立公司品牌形象，助推企业高质量发展。 特此公告。 精华制药集团股份有限公司董事会 2025 年 9 月 17 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 近日，由公司孙公司山东鲁化森萱新材料有限公司（以下简称"鲁化森萱"） 牵头制定的《1,3-二氧戊环》行业标准（标准号：HG/T6387-2025）通过国家标 委会评审，并经中华人民共和国工业和信息化部发布公告，该标准于 2026 年 3 月 1 日起正式实施。 ...

证券日报网讯精华制药（002349）9月12日在互动平台回答投资者提问时表示，孙公司鲁化森萱生产的 二氧五环目前未用于固态电池，公司是国内二氧五环主要供应商之一。 ...

格隆汇9月12日丨精华制药(002349.SZ)在投资者互动平台表示，孙公司鲁化森萱生产的二氧五环目前未 用于固态电池，公司是国内二氧五环主要供应商之一。 ...

（文章来源：每日经济新闻） 精华制药（002349.SZ）9月12日在投资者互动平台表示，孙公司鲁化森萱生产的二氧五环目前未用于固 态电池，公司是国内二氧五环主要供应商之一。 每经AI快讯，有投资者在投资者互动平台提问：孙公司鲁化森萱生产的二氧五环是否可以用于固态电 池，是固态电池上有原材料和介质吗？目前二氧五环产量在行业份额占比有多大？ ...

精华制药（002349.SZ）9月11日在投资者互动平台表示，孙公司鲁化森萱生产的二氧五环主要用于共聚 甲醛的合成，部分用于磷酸铁锂路线一次电池的电解液，目前尚未用于固态电池。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：孙公司鲁化森萱生产的二氧五环用于固态电池的年产 能是多少，有无扩张生产？ ...

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]